The influence of inhalation device for bronchodilators on the results of therapy in primary care patients with bronchial asthma (BA) and chronic obstructive pulmonary disease (COPD) Source: Annual Congress 2008 - Asthma control or asthma severity Year: 2008
Clinical effectiveness of nebulized budesonide in the treatment of acute asthma and exacerbations of chronic obstructive pulmonary disease (COPD) Source: Eur Respir J 2001; 18: Suppl. 33, 146s Year: 2001
The efficacy of formoterol in patients with chronic obstructive pulmonary disease (COPD) is not influenced by concomitant corticosteroid use Source: Eur Respir J 2001; 18: Suppl. 33, 515s Year: 2001
Influence of bronchodilators on pulmonary hypertension in patients with chronic obstructive pulmonary disease (COPD) and COPD concomitant with bronchial asthma Source: Eur Respir J 2004; 24: Suppl. 48, 521s Year: 2004
Formoterol demonstrates bronchodilator efficacy in patients with reversible or poorly reversible chronic obstructive pulmonary disease (COPD), regardless of concomitant corticosteroid use Source: Eur Respir J 2001; 18: Suppl. 33, 177s Year: 2001
Bronchodilatory effects of formoterol in patients with chronic obstructive pulmonary disease (COPD) are not influenced by concomitant corticosteroid use Source: Eur Respir J 2001; 18: Suppl. 33, 514s Year: 2001
Osteoporosis risk assessment in elderly male patients with COPD who use inhaled corticosteroids Source: Annual Congress 2006 - COPD therapy Year: 2006
The safety of sputum induction in patients with exacerbation of severe and very severe COPD (chronic obstructive pulmonary disease) Source: Annual Congress 2008 - Organisation of care and management of COPD Year: 2008
Formoterol turbuhaler is an effective maintenance and maintenance plus reliever therapy in patients with chronic obstructive pulmonary disease (COPD) irrespective of the level of lung function impairment and reversibility Source: Eur Respir J 2002; 20: Suppl. 38, 243s Year: 2002
Can we predict the outcomes of treatment of patients with severe exacerbation of chronic obstructive pulmonary disease (COPD)? Source: Eur Respir J 2001; 18: Suppl. 33, 241s Year: 2001
Additive benefits of tiotropium in asthmatics and in patients with asthma complicated chronic obstructive pulmonary disease Source: Eur Respir J 2007; 30: Suppl. 51, 546s Year: 2007
Audit of inhaled corticosteroid prescription in chronic obstructive pulmonary disease (COPD) Source: Annual Congress 2010 - COPD: management Year: 2010
Mechanism by which inhaled bronchodilators prevent exacerbations in chronic obstructive pulmonary disease Source: Annual Congress 2013 –Asthma and COPD drugs: efficacy, safety and pharmacoeconomics Year: 2013
Effects of inhaled corticosteroids on airway inflammations of different types in patients with chronic obstructive pulmonary disease or asthma in stable phase Source: Annual Congress 2009 - Aspects of clinical asthma Year: 2009
Inhaled maintenance therapy and risk of first or subsequent emergency department visit/hospitalization in patients with COPD Source: Annual Congress 2006 - COPD therapy Year: 2006
Calorie-intake in patients hospitalized for an acute COPD exacerbation Source: Annual Congress 2007 - Nurses' involvement in the follow-up of patients with COPD and lung cancer Year: 2007
Bronchodilator responsiveness in patients with COPD Source: Eur Respir J 2008; 31: 742-750 Year: 2008
What is the optimal treatment strategy for chronic obstructive pulmonary disease exacerbations? Source: Eur Respir J 2002; 19: 928-935 Year: 2002
Inhaled corticosteroids and the risk of a first exacerbation in COPD patients Source: Eur Respir J 2004; 23: 692-697 Year: 2004
Where current pharmacological therapies fall short in COPD: symptom control is not enough Source: Eur Respir Rev 2007; 16: 98-104 Year: 2007